DS-2325a ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
160	Congenital ichthyosis	2

160. Congenital ichthyosis

---

Clinical trials : 42 /  Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05583669 (ClinicalTrials.gov)	November 8, 2022	13/10/2022	A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects	A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects	Netherton Syndrome	Drug: DS-2325a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Recruiting	18 Years	50 Years	All	24	Phase 1	United States
2	NCT05388903 (ClinicalTrials.gov)	June 20, 2022	19/5/2022	A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects	A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects	Netherton Syndrome	Drug: DS-2325a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Completed	18 Years	45 Years	All	64	Phase 1	United States